Details for Patent: 9,226,892
Which drugs does patent 9,226,892 protect, and when does it expire?
Patent 9,226,892 protects VAZALORE and is included in one NDA.
This patent has twenty patent family members in nine countries.
Summary for Patent: 9,226,892
| Title: | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| Abstract: | Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia. |
| Inventor(s): | Upendra K. Marathi, Susann Edler Childress, Shaun L. Gammill, Robert W. Strozier |
| Assignee: | Plx Acquisition Company LLC |
| Application Number: | US13/791,189 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,226,892
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE | ⤷ Start Trial | ||||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TEMPORARY RELIEF OF MINOR ACHES AND PAINS | ⤷ Start Trial | ||||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TEMPORARY REDUCTION OF FEVER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,226,892
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012315545 | ⤷ Start Trial | |||
| Canada | 2850187 | ⤷ Start Trial | |||
| China | 103957888 | ⤷ Start Trial | |||
| European Patent Office | 2760433 | ⤷ Start Trial | |||
| Hong Kong | 1200098 | ⤷ Start Trial | |||
| Japan | 2014531460 | ⤷ Start Trial | |||
| Japan | 2017222650 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
